Immediate Reports All 2016 2017 2018 2019 2020 Astellas (about 0.6%) – announced the cancellation of the agreement with Juventas Cardiacsense (5.67%), has signed an exclusive distribution agreement for the sale of medical watches in the UAE Calling of Annual & special meeting for Oct 14, 2020 Cardiacsense (about 5.67%) has signed an exclusive distribution agreement for the sale of medical watches in Switzerland TrainPain (about 5.69%) – Beginning of an experiment for treatment using the AI-based digital platform Invest $ 250,000 in Ora Smart as part of an investment round of $ 3m according to $ 10m (before) – following the reports Receiving additional consideration for a merger transaction between Remedy (9%) with Optimize Results of general meeting Invest $ 100 in a fundraising round at E.F.A, hold after 8.15% Cardiacsense (5.67%) received a medical certificate for medical clock for heart rate monitoring and diagnosis of atrial fibrillation Memorandum of Understanding for the investment of $ 250,000 in Ora Air (engaged in air quality), against 1.93% in Ora Air Calling of special meeting of Aug 20, 2020 Continues to negotiate a binding agreement for a business partnership with CD’X CD’X (held 7%) began commercial-marketing OISPSA test for the Cleveland Clinic Urology Department Cardiacsense (approx. 5.87%) – Starting an Experiment on the Smart Watch for Breathing Rhythm at Ichilov Hospital Cardiacsense Capital Raising Round (5.33%) – The Company Will Invest $ 250, Hold 5.87% of Equity Result of general meeting Cardiacsense has signed an exclusive distribution agreement Cardiacsence (approximately 6.16%) in exclusive distribution agreement for medical watches it develops Cardiacsense (6.16%), has signed an exclusive distribution deal to sell medical watches Cardiacsense (6.34%), signed two exclusive distribution agreements for the sale of medical watches IFA (9.09%), has received the right to grant permission from the Innovation Authority for the R&D project for a mobile blood test device Cardiacsense (6.34%) – Positive Clinical Trial Clinical Trial Detection for Cardiac Disorders Result of general meeting Calling of general & special meeting for June 7, 2020 Cardiacsense (about 6.34%), signed an exclusive distribution agreement for distributing medical watches in Australia and New Zealand Subsidiary (approximately 6.34%), in an exclusive distribution agreement in South Africa for the sale of medical watches for the detection of cardiac arrhythmias A meeting convened on April 26, 2020 is adjourned on May 3, 2020 Memorandum of Understanding (7.97%) CD’X will provide exclusive marketing and diagnostic testing for prostate cancer diagnosis A meeting convened for 6.4.20 is adjourned for 26.4.20 discussion with shareholders of a company Merhavia has signed an agreement to cancel an option to buy Liventhal shares Extends on the date of the 2019 Periodic Report The court ordered the transfer of part of the proceeds from the sale of a property in Bat Shlomo to the company Calling for general meeting of Apr 6, 2020 Cardiacsense (7.58%), Signs First Distribution Agreement for the Sale of Medical Watches in South America, $ 1.5 Million for 3 Years Calling of spicial meeting for Apr, 6 2020 Board of Directors Approves Company Participation in Recruitment Rounds at Company Holds CD’X and Cardiacsense Court decision, settlement / compromise / proceedings Results of general meeting Results of meeting of Nov 5, 2019 CDX (held about 7.5%) FDA approval to test for prostate cancer as a breakthrough device Calling of meeting for Nov 13, 2019 A meeting conve19ned for October 6, 2019 , is adjourned for November 5, 2019, in light of the company’s request Remedy (about 9.45%) has completed an inverted triple merger agreement with OptimizerX Calling of special meeting for Oct 6, 2019 RMDY (about 6%) in merger agreement with OPTIMIZERX for cash and OPTIMIZERX shares, $ 1.1-3.7m External Investor Investments Closes $ 3 Million in Cleveland Diagnostics against Shares in Up to $ 6 Million The Company’s Board of Directors has approved a dividend distribution policy Decided not to pursue investment negotiations with Spectra Kan The transaction for investment in Violi – Debt cannabis was completed CD’X (about 7.85%) in understandings with investors investing $ 3m against shares in a round of up to $ 6m, reflecting a value of $ 65m Non-binding letter of intent to sell RMDY (held -6%) CD’X (approximately 7.85%) – Promotes Trials for FDA Application for Prostate Cancer Diagnostic Product Letter of Intent Does Not Require $ 1 in Debt Cann Spectrum in Medical Cannabis Violi signed the license agreement under the Violi Investment Company agreement A milestone was completed in an IPA investment agreement, holding 9.09% Cardiacsense entered into the Memorandum of Understanding with a leading European medical center RMDY, Approximately (6.06%), in a digital medicine services agreement with a strategic client Letter from the CEO to the company’s shareholders Results of general meeting Cardiacsense Expression – 7.17% – Positive results for first trial of detection of elevated fibrillation Calling of general meeting for Mar 14, 2019 -Update An agreement to invest NIS 1 million in a company developing a mobile device for diagnosing infectious diseases against 9.3% of the capital An investment agreement has been signed in the Company, and will invest about $ 400 a for 20% Negotiations to formulate an investment agreement with the cannabis company Calling of general meeting of March 14, 2019 Arrangement / Compromise / Freezing Proceedings, Appeal to Court Board decisions-remuneration policy, terms of employment of CEO and chairman, consulting services and appointment of board of directors, subject to approval Cardiacsense (approximately 7.45%) – Initiation of an Initial Clinical Trial to Detect Increased Butterfly in Ambulatory Conditions It was decided to expand activity and enter R&D in medical cannabis Invest in G4P – Digital Healthcare Company – NIS 600,000 for 6% G4P Shares Execution approved the sale of the property in Bat Shlomo at NIS 4.1m Letter from CEO to shareholders – summary of the first 6 months of 2018 Cardiacsense completed 500K$ investment round on a 20M$ company valuation Positive Results in a Multi-Center Clinical Trial of CDx Juventas’s trial’s end-points for closing wounds on a diabetic foot not met CEO’s letter to shareholders – annual summary Memorandum of Understanding for investing $500,000 in Valens in exchange for allocation of about 6.25% of preferred shares Libental fully repaid loan worth NIS 7 million to Merchavia CDX signs exclusive commercialization agreement with Genomic granting a license to develop and commercialize tests for early diagnosis of prostate cancer CardiacSense completed raising funds from an external investor, after completion the company holds 7.86% Vacation of the property in Beit Shlomo completed, receiver appointed by the company will work for its sale Participation in the investment round of CardiacSense Ltd. Helsinki Committee approves start of trial for CardiacSense’s product Engaging in an investment agreement in CardiacSense Publishing an article in European Urology magazine about the final findings in CDX’s clinical trial Engaging in a non-binding Memorandum of Understanding to invest in CardiacSense The company is examining investing between NIS 1 million and NIS 4 million in each of 1-3 companies in the field of biomed and life sciences Merchavia Holdings has completed the sale of the balance of shares of Libental, owned by Baruch Ofir Merchavia Holdings will complete the sale of shares in Libental to Baruch Ofir for NIS 1.8 million – continued The company will invest $500,000 in Juventas as part of an investment round for 0.65% of preferred shares The company will sell its holdings in Libental for about NIS 3.3 million The deal has been completed for the sale of the full rights in T.G.R. to Dashan Intermediary results in the trial of CDX’s product for early diagnosis of prostate cancer The investment deal by a third party in CDX has been completed The third party will invest about $1.25 million in CDX The agreement is contingent on the sale of full rights in T.G.R. to Dashan for about NIS 7 million
Cardiacsense (5.67%), has signed an exclusive distribution agreement for the sale of medical watches in the UAE
Cardiacsense (about 5.67%) has signed an exclusive distribution agreement for the sale of medical watches in Switzerland
TrainPain (about 5.69%) – Beginning of an experiment for treatment using the AI-based digital platform
Invest $ 250,000 in Ora Smart as part of an investment round of $ 3m according to $ 10m (before) – following the reports
Cardiacsense (5.67%) received a medical certificate for medical clock for heart rate monitoring and diagnosis of atrial fibrillation
Memorandum of Understanding for the investment of $ 250,000 in Ora Air (engaged in air quality), against 1.93% in Ora Air
Cardiacsense (approx. 5.87%) – Starting an Experiment on the Smart Watch for Breathing Rhythm at Ichilov Hospital
Cardiacsence (approximately 6.16%) in exclusive distribution agreement for medical watches it develops
IFA (9.09%), has received the right to grant permission from the Innovation Authority for the R&D project for a mobile blood test device
Cardiacsense (about 6.34%), signed an exclusive distribution agreement for distributing medical watches in Australia and New Zealand
Subsidiary (approximately 6.34%), in an exclusive distribution agreement in South Africa for the sale of medical watches for the detection of cardiac arrhythmias
Memorandum of Understanding (7.97%) CD’X will provide exclusive marketing and diagnostic testing for prostate cancer diagnosis
The court ordered the transfer of part of the proceeds from the sale of a property in Bat Shlomo to the company
Cardiacsense (7.58%), Signs First Distribution Agreement for the Sale of Medical Watches in South America, $ 1.5 Million for 3 Years
Board of Directors Approves Company Participation in Recruitment Rounds at Company Holds CD’X and Cardiacsense
A meeting conve19ned for October 6, 2019 , is adjourned for November 5, 2019, in light of the company’s request
External Investor Investments Closes $ 3 Million in Cleveland Diagnostics against Shares in Up to $ 6 Million
CD’X (about 7.85%) in understandings with investors investing $ 3m against shares in a round of up to $ 6m, reflecting a value of $ 65m
CD’X (approximately 7.85%) – Promotes Trials for FDA Application for Prostate Cancer Diagnostic Product
Cardiacsense Expression – 7.17% – Positive results for first trial of detection of elevated fibrillation
An agreement to invest NIS 1 million in a company developing a mobile device for diagnosing infectious diseases against 9.3% of the capital
Board decisions-remuneration policy, terms of employment of CEO and chairman, consulting services and appointment of board of directors, subject to approval
Cardiacsense (approximately 7.45%) – Initiation of an Initial Clinical Trial to Detect Increased Butterfly in Ambulatory Conditions
Memorandum of Understanding for investing $500,000 in Valens in exchange for allocation of about 6.25% of preferred shares
CDX signs exclusive commercialization agreement with Genomic granting a license to develop and commercialize tests for early diagnosis of prostate cancer
CardiacSense completed raising funds from an external investor, after completion the company holds 7.86%
Vacation of the property in Beit Shlomo completed, receiver appointed by the company will work for its sale
The company is examining investing between NIS 1 million and NIS 4 million in each of 1-3 companies in the field of biomed and life sciences
Merchavia Holdings will complete the sale of shares in Libental to Baruch Ofir for NIS 1.8 million – continued
The company will invest $500,000 in Juventas as part of an investment round for 0.65% of preferred shares
